

## Nanterinone

## Chemical Properties


CAS No. : 102791-47-9

Formula: C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O

Molecular Weight: 253.3

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Nanterinone (UK 61260), an orally available partial phosphodiesterase inhibitor, is a novel positive inotropic and balanced vasodilator compound. Nanterinone, when administered orally, results in significant improvements in acute haemodynamics, which may depend on pre-existing left ventricular filling pressures. Nanterinone is a novel positive inotropic and balanced vasodilator that has demonstrated acute hemodynamic effects in patients with mild to moderate heart failure.
Targets(IC50)	PDE
In vivo	Nanterinone (2 mg ; oral ; patients NYHA class II-III ; ACE) has a significant acute hemodynamic improvement and is well tolerated. Although changes in left ventricular filling pressure are more pronounced in patients with elevated pre-existing PCWP, cardiac pump function improves equally in patients with normal or low left ventricular filling pressure at baseline.[1]

## Solubility Information

Solubility	DMSO: Slightly soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	3.9479 mL	19.7394 mL	39.4789 mL
5 mM	0.7896 mL	3.9479 mL	7.8958 mL
10 mM	0.3948 mL	1.9739 mL	3.9479 mL
50 mM	0.079 mL	0.3948 mL	0.7896 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Remme WJ, et al. Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure. *Cardiovasc Drugs Ther.* 1996 May ; 10(2):137-144.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481